NCT02683083View on ClinicalTrials.gov

Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 5, 2018

Study Completion Date

February 5, 2018

Conditions
Healthy VolunteersBreast Cancer
Interventions
BIOLOGICAL

[131I]-SGMIB Anti-HER2 VHH1

Trial Locations (1)

1090

UZ Brussel, Brussels

Sponsors

Lead Sponsor

Precirix
All Listed Sponsors
lead

Precirix

INDUSTRY

NCT02683083 - Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients | Biotech Hunter | Biotech Hunter